MiNK Therapeutics confirms active discussions for combination trials and strategic investments

MiNK Therapeutics, Inc.

Company is in active discussions with multiple parties for potential combination trials of agenT-797.
Discussions also include potential strategic minority investments in MiNK.
No binding arrangements have been publicly disclosed; no assurance of final agreements.
Clarification issued in response to third-party postings regarding potential trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.